Shinsuke Kusakabe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shinsuke Kusakabe has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Kentaro Fukushima
Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan
4 shared publications Daisuke Motooka
Integrated Frontier Research for Medical Science Division Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University Suita Japan
3 shared publicationsHirohiko Shibayama
Department of Hematology and Oncology Osaka University Graduate School of Medicine Suita Japan
3 shared publicationsShota Nakamura
Integrated Frontier Research for Medical Science Division Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University Suita Japan
3 shared publicationsTakafumi Yokota
Department of Hematology and Oncology Osaka University Graduate School of Medicine Suita Japan
3 shared publicationsAkihisa Hino
Department of Haematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan
2 shared publications
Latest Publications
- 19 August 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (11) , 1573-1575
Prognostic factors of second allogeneic hematopoietic stem cell transplantation for relapsed or refractory myelodysplastic syndromes: nationwide registry analysis
- 19 August 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (11) , 1573-1575
Prognostic factors of second allogeneic hematopoietic stem cell transplantation for relapsed or refractory myelodysplastic syndromes: nationwide registry analysis
- Open Access
- 7 September 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (5) , 2187-2191
Enterococcus proliferates via the phosphotransferase system in the disrupted gut microbiota after allogeneic haematopoietic stem cell transplantation
- 7 September 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (5) , 2187-2191
Open AccessEnterococcus proliferates via the phosphotransferase system in the disrupted gut microbiota after allogeneic haematopoietic stem cell transplantation
- Open Access
- 2 March 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (6) , 795-802
Clostridium butyricum MIYAIRI 588 contributes to the maintenance of intestinal microbiota diversity early after haematopoietic cell transplantation
In patients undergoing haematopoietic stem-cell transplantation (HSCT), the intestinal microbiota plays an important role in prognosis, transplant outcome, and complications such as graft-versus-host disease (GVHD). Our prior research revealed that patients undergoing HSCT substantially differed from healthy controls. In this retrospective study, we showed that administering Clostridium butyricum MIYAIRI 588 (CBM588) as a live biotherapeutic agent is associated with maintaining intestinal microbiota in the early post-HSCT period. Alpha diversity, which reflects species richness, declined considerably in patients who did not receive CBM588, whereas it remained consistent in those who received CBM588. In addition, β-diversity analysis revealed that CBM588 did not alter the gut microbiota structure at 7–21 days post-HSCT. Patients who developed GVHD showed structural changes in their microbiota from the pre-transplant period, which was noticeable on day 14 before developing GVHD. Enterococcus was significantly prevalent in patients with GVHD after HSCT, and the population of Bacteroides was maintained from the pre-HSCT period through to the post-HSCT period. Patients who received CBM588 exhibited a contrasting trend, with lower relative abundances of both genera Enterococcus and Bacteroides. These results suggest that preoperative treatment with CBM588 could potentially be beneficial in maintaining intestinal microbiota balance.
- 2 March 2024
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (6) , 795-802
Open AccessClostridium butyricum MIYAIRI 588 contributes to the maintenance of intestinal microbiota diversity early after haematopoietic cell transplantation
In patients undergoing haematopoietic stem-cell transplantation (HSCT), the intestinal microbiota plays an important role in prognosis, transplant outcome, and complications such as graft-versus-host disease (GVHD). Our prior research revealed that patients undergoing HSCT substantially differed from healthy controls. In this retrospective study, we showed that administering Clostridium butyricum MIYAIRI 588 (CBM588) as a live biotherapeutic agent is associated with maintaining intestinal microbiota in the early post-HSCT period. Alpha diversity, which reflects species richness, declined considerably in patients who did not receive CBM588, whereas it remained consistent in those who received CBM588. In addition, β-diversity analysis revealed that CBM588 did not alter the gut microbiota structure at 7–21 days post-HSCT. Patients who developed GVHD showed structural changes in their microbiota from the pre-transplant period, which was noticeable on day 14 before developing GVHD. Enterococcus was significantly prevalent in patients with GVHD after HSCT, and the population of Bacteroides was maintained from the pre-HSCT period through to the post-HSCT period. Patients who received CBM588 exhibited a contrasting trend, with lower relative abundances of both genera Enterococcus and Bacteroides. These results suggest that preoperative treatment with CBM588 could potentially be beneficial in maintaining intestinal microbiota balance.
- 5 December 2022
- Published by Wiley in British Journal of Haematology
- Vol. 201 (4) , 725-737
Prolonged gut microbial alterations in post‐transplant survivors of allogeneic haematopoietic stem cell transplantation
Summary: Dysbiosis of the gut microbiota has been reported to increase early complications after allogeneic haematopoietic stem cell transplantation (allo‐HSCT). However, it remains unclear whether gut microbial alterations persist during late complications, such as chronic graft‐versus‐host disease (cGVHD) or secondary cancers. Here, we analysed the gut microbiota of 59 patients who survived for 1–21.7 years (median, 6.4 years) after allo‐HSCT. Long‐term survivors showed lower gut microbial diversity than the age‐ and sex‐matched healthy controls. This decreased diversity was reflected in the reduced abundance of the butyrate‐producing bacteria. Patients with a history of grade 3 acute graft‐versus‐host disease (aGVHD) exhibited higher Veillonella abundance than patients with a history of grade 1–2 or non‐aGVHD cases. The abundance of Faecalibacterium showed no decrease only in limited cGVHD cases. Additionally, the microbial structure in the secondary cancer group was significantly different (p < 0.05) from that in the non‐secondary cancer group. This study is the first to show that microbial dysbiosis is present over a 10‐year lifetime after discharge following allo‐HSCT. Our results suggest that these prolonged gut microbial alterations may be associated with the development and exacerbation of late complications in post‐transplant survivors.
- 5 December 2022
- Published by Wiley in British Journal of Haematology
- Vol. 201 (4) , 725-737
Prolonged gut microbial alterations in post‐transplant survivors of allogeneic haematopoietic stem cell transplantation
Summary: Dysbiosis of the gut microbiota has been reported to increase early complications after allogeneic haematopoietic stem cell transplantation (allo‐HSCT). However, it remains unclear whether gut microbial alterations persist during late complications, such as chronic graft‐versus‐host disease (cGVHD) or secondary cancers. Here, we analysed the gut microbiota of 59 patients who survived for 1–21.7 years (median, 6.4 years) after allo‐HSCT. Long‐term survivors showed lower gut microbial diversity than the age‐ and sex‐matched healthy controls. This decreased diversity was reflected in the reduced abundance of the butyrate‐producing bacteria. Patients with a history of grade 3 acute graft‐versus‐host disease (aGVHD) exhibited higher Veillonella abundance than patients with a history of grade 1–2 or non‐aGVHD cases. The abundance of Faecalibacterium showed no decrease only in limited cGVHD cases. Additionally, the microbial structure in the secondary cancer group was significantly different (p < 0.05) from that in the non‐secondary cancer group. This study is the first to show that microbial dysbiosis is present over a 10‐year lifetime after discharge following allo‐HSCT. Our results suggest that these prolonged gut microbial alterations may be associated with the development and exacerbation of late complications in post‐transplant survivors.
- 8 March 2021
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 56 (7) , 1728-1731
Low diversity of gut microbiota in the early phase of post-bone marrow transplantation increases the risk of chronic graft-versus-host disease
- 8 March 2021
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 56 (7) , 1728-1731
Low diversity of gut microbiota in the early phase of post-bone marrow transplantation increases the risk of chronic graft-versus-host disease
- 30 September 2019
- Published by Wiley in British Journal of Haematology
- Vol. 188 (3) , 438-449
Pre‐ and post‐serial metagenomic analysis of gut microbiota as a prognostic factor in patients undergoing haematopoietic stem cell transplantation
Summary: The human gut harbours diverse microorganisms, and gut dysbiosis has recently attracted attention because of its possible involvement in various diseases. In particular, the lack of diversity in the gut microbiota has been associated with complications of haematopoietic stem cell transplantation (HSCT), such as infections, acute graft‐versus‐host disease and relapse of primary disease, which lead to a poor prognosis. However, few studies have serially examined the composition of the intestinal microbiota after HSCT. In this study, we demonstrated, using next‐generation sequencing of the bacterial 16S ribosomal RNA gene, combined with uniFrac distance analysis, that the intestinal microbiota of patients undergoing allogeneic HSCT substantially differed from that of healthy controls and recipients of autologous transplants. Faecal samples were obtained daily throughout the clinical course, before and after transplantation. Notably, the proportions of Bifidobacterium and genera categorized as butyrate‐producing bacteria were significantly lower in patients with allogeneic HSCT than in healthy controls. Furthermore, among allogeneic transplant recipients, a subgroup with a preserved microbiota composition showed a benign course, whereas patients with a skewed microbiota showed a high frequency of complications and mortality after transplantation. Thus, we conclude that the stability of intestinal microbiota is critically involved in outcomes of HSCT.
- 30 September 2019
- Published by Wiley in British Journal of Haematology
- Vol. 188 (3) , 438-449
Pre‐ and post‐serial metagenomic analysis of gut microbiota as a prognostic factor in patients undergoing haematopoietic stem cell transplantation
Summary: The human gut harbours diverse microorganisms, and gut dysbiosis has recently attracted attention because of its possible involvement in various diseases. In particular, the lack of diversity in the gut microbiota has been associated with complications of haematopoietic stem cell transplantation (HSCT), such as infections, acute graft‐versus‐host disease and relapse of primary disease, which lead to a poor prognosis. However, few studies have serially examined the composition of the intestinal microbiota after HSCT. In this study, we demonstrated, using next‐generation sequencing of the bacterial 16S ribosomal RNA gene, combined with uniFrac distance analysis, that the intestinal microbiota of patients undergoing allogeneic HSCT substantially differed from that of healthy controls and recipients of autologous transplants. Faecal samples were obtained daily throughout the clinical course, before and after transplantation. Notably, the proportions of Bifidobacterium and genera categorized as butyrate‐producing bacteria were significantly lower in patients with allogeneic HSCT than in healthy controls. Furthermore, among allogeneic transplant recipients, a subgroup with a preserved microbiota composition showed a benign course, whereas patients with a skewed microbiota showed a high frequency of complications and mortality after transplantation. Thus, we conclude that the stability of intestinal microbiota is critically involved in outcomes of HSCT.